Gilat Satellite Networks reported Q3 2026 revenues of $116.2 million, slightly down from $117.7 million a year earlier, but improved GAAP operating income to $7.9 million and raised adjusted EBITDA by 13% to $17.6 million. Non-GAAP net income grew 21% to $14.3 million, driven by strong cost control despite currency challenges and a major customer bankruptcy. The company is on track to close its acquisition of Comtech by year-end, which is expected to more than double its defense segment revenues in 2027, reflecting a strategic shift toward defense and secure communications. Gilat also revised its 2026 revenue guidance to $455-$475 million and adjusted EBITDA to $61-$63 million, highlighting ongoing opportunities in satellite ground infrastructure and new satellite constellations.
Gilat Satellite Networks' Q3 2026 results provide context for readers. As of Nov 10, 2026 18:12 WIB, among 150 priced Technology-sector US stocks tradable on Pluang, 51 rose and 89 fell. Notable movers include ASX at USD 36.43 with a 1-day change of +6.02% and a typical hold time on Pluang of 50 days, WIX at USD 66.74 down 4.32%, and TTWO at USD 215.47 up 3.89%.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
